Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Results of pretransplant treatment of hepatorenal syndrome with terlipressin.

Solà E, Cárdenas A, Ginès P.

Curr Opin Organ Transplant. 2013 Jun;18(3):265-70. doi: 10.1097/MOT.0b013e3283614c7a. Review.

PMID:
23652609
2.

Terlipressin in hepatorenal syndrome: Evidence for present indications.

Rajekar H, Chawla Y.

J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:109-14. doi: 10.1111/j.1440-1746.2010.06583.x. Review.

PMID:
21199521
3.

Hepatorenal syndrome and novel advances in its management.

Fabrizi F, Aghemo A, Messa P.

Kidney Blood Press Res. 2013;37(6):588-601. doi: 10.1159/000355739. Epub 2013 Dec 5. Review.

4.

Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.

Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P; Terlipressin Study Group.

Liver Transpl. 2011 Nov;17(11):1328-32. doi: 10.1002/lt.22395.

5.

Review article: pharmacological treatment of hepatorenal syndrome.

Ginès P, Torre A, Terra C, Guevara M.

Aliment Pharmacol Ther. 2004 Sep;20 Suppl 3:57-62; discussion 63-4. Review.

6.

Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?

Piano S, Morando F, Fasolato S, Cavallin M, Boscato N, Boccagni P, Zanus G, Cillo U, Gatta A, Angeli P.

J Hepatol. 2011 Aug;55(2):491-6. doi: 10.1016/j.jhep.2011.02.002. Epub 2011 Feb 18.

7.

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.

Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R.

J Gastroenterol Hepatol. 2002 Aug;17(8):882-8.

PMID:
12164964
8.

Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.

Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF.

Eur J Gastroenterol Hepatol. 2002 Feb;14(2):153-8.

PMID:
11981339
9.

Hepatorenal syndrome.

Angeli P, Morando F, Cavallin M, Piano S.

Contrib Nephrol. 2011;174:46-55. doi: 10.1159/000329235. Epub 2011 Sep 9. Review.

PMID:
21921608
10.

[The role of terlipressin in hepatorenal syndrome].

Forcellini S, Fabbian F.

G Ital Nefrol. 2010 Sep-Oct;27(5):469-76. Italian.

PMID:
20922678
11.

Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.

Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V.

Liver Int. 2013 Sep;33(8):1187-93. doi: 10.1111/liv.12179. Epub 2013 Apr 21.

PMID:
23601499
12.

Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.

Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, Mendoza E, Segura JJ.

Ann Hepatol. 2009 Jul-Sep;8(3):207-11.

PMID:
19841499
13.

Hepatorenal syndrome in patients with cirrhosis.

Moreau R.

J Gastroenterol Hepatol. 2002 Jul;17(7):739-47. Review.

PMID:
12121502
14.

Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice.

Angeli P, Gines P.

J Hepatol. 2012 Nov;57(5):1135-40. doi: 10.1016/j.jhep.2012.06.024. Epub 2012 Jun 26. Review.

15.

Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.

Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A.

J Hepatol. 2007 Oct;47(4):499-505. Epub 2007 May 24.

PMID:
17560680
16.

Terlipressin and albumin combination treatment in hepatorenal syndrome.

Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A.

Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccciii-cccv.

PMID:
15244209
17.

Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.

Ganne-Carrié N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP.

Dig Dis Sci. 1996 Jun;41(6):1054-6.

PMID:
8654133
18.

An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.

Sharma P, Kumar A, Shrama BC, Sarin SK.

Am J Gastroenterol. 2008 Jul;103(7):1689-97. doi: 10.1111/j.1572-0241.2008.01828.x. Epub 2008 Jun 28.

PMID:
18557715
19.

Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.

Testro AG, Wongseelashote S, Angus PW, Gow PJ.

J Gastroenterol Hepatol. 2008 Oct;23(10):1535-40. Epub 2008 Sep 3.

PMID:
17784863
20.

Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes.

Rodriguez E, Henrique Pereira G, Solà E, Elia C, Barreto R, Pose E, Colmenero J, Fernandez J, Navasa M, Arroyo V, Ginès P.

Liver Transpl. 2015 Nov;21(11):1347-54. doi: 10.1002/lt.24210.

Supplemental Content

Support Center